Effects of Radiation Therapy Based on Pemetrexed Combination with Cisplation or Carboplatin Regimen on Peripheral Lymphocyte Subsets in Patients with Non-small Cell Lung Cancer
-
摘要: 目的 探讨培美曲塞（pemetrexed）联合顺铂（cisplatin）或卡铂（carboplatin）治疗方案对非小细胞肺癌患者外周血淋巴细胞表型的影响。方法45例经病理学或细胞学确诊的非小细胞肺癌患者，采用培美曲塞500 mg/m2，第1天静脉滴注；顺铂25 mg/m2，第1～3天或卡铂按AUC=5计算剂量，第2天静脉滴注，21天为一周期，毎例患者至少治疗2周期，有可测量病灶者进行疗效评价。应用流式细胞仪检测化疗前和化疗后第7天外周血CD3+、CD4+、CD8+、CD16+56+、CD19+细胞的百分率和CD4+/CD8+比值。结果非小细胞肺癌患者经培美曲塞联合含铂方案化疗后CD4+、CD4+/CD8+、CD16+56+较化疗前升高（P=0.032），CD3+、CD8+、CD19+化疗前后差异无统计学意义（P>0.05）；临床分期为ⅢB～Ⅳ期的患者化疗前CD3+、CD4+、CD4+/CD8+和CD16+56+较ⅠB～ⅢA期患者低（P=0.029），化疗后两者比较差异无统计学意义（P>0.05）；化疗有效者CD3+、CD4+、CD4+/CD8+比值均显著增高（P=0.008）。结论非小细胞肺癌患者，尤其是晚期患者机体免疫功能低下。培美曲塞联合含铂方案化疗打破了原有的抗肿瘤免疫抑制状态，机体有可能通过免疫重建增强抗肿瘤免疫应答。Abstract: Objective To evaluate effects of radiation therapy based on pemetrexed combination with cisplatin or carboplatin regimen on the peripheral lymphocyte subsets in patients with non-small cell lung cancer(NSCLC). Methods A total of forty-five patients with a pathologic diagnosis enrolled in this study were treated with pemetrexed 500 mg/m2 infusion on day 1 and cisplatin 25 mg/m2 infusion on day 1 to 3 or carboplatin area under the curve(AUC)5 infusion on day 2.The peripheral blood was collected before and five days after chemotherapy.Every patient must be evaluated with the flow cytometry for CD3+,CD4+,CD8+,CD4+/CD8+,CD16+56+ and CD19+. Results The expressive rates of CD4+,CD16+56+ and CD4+/CD8+ in peripheral blood in post-treatment patients were higher than that in pre-treatment samples (P=0.032).No evident case of changes of CD3+,CD8+,and CD19+ positive cell percentage were observed after chemotherapy(P>0.05).Before chemotherapy,the positive percentage of CD3+,CD4+,CD16+56+ and the ratio of CD4+/CD8+ in NSCLC ⅢB～Ⅳ clinical stage were statistically significantly lower than those in ⅠB～ⅢA clinical stage patients（P=0.029）,but were not different from those after chemotherapy(P>0.05).CD3+,CD4+ and the ratio of CD4+/CD8+ in the effective group were highter than those in pre-treatment samples（P=0.008）. Conclusion The immune function of advanced stage NSCLC patients is evidently suppressed.Pemetrexed combination with cisplatin or carboplatin regimen for NSCLC may break up anti-tumor immune suppression,then a transient immune suppression condition is reversed by the body rebuilding to enhance the immune function.
-
Key words:
- Pemetrexed /
- Non-small cell lung cancer /
- Lymphocyte subsets /
- Flow cytometry
-
-
[1] Huang X,Chen LB.Immunomodulatory features of chemotherapeutics[J].Yi Xue Yan Jiu Sheng Xue Bao,2010,23 (1):76-81.[黄香，陈龙邦.化疗药物的免疫调节作用[J].医学研究生学报，2010，23(1)：76-81.] [2] Chu Y，Wang LX，Yang G，et al .Efficacy of GM-CSF-producing tumor vaccine after docetaxel chemotherapy in mice bearing established Lewis lung carcinoma [J].J Immunother，2006，29(4)：367 -80. [3] Metro G，Chiari R，Mare M，et al.Carboplatin plus pemetrexed for platinum-pretreated，advanced non-small cell lung cancer：a retrospective study with pharmacogenetic evaluation[J].Cancer Chemother Pharmacol，2011，68(6)： 1405-12. [4] Kim HS，Lee GW，Kim GH，et al.A phase II study of pemetrexed and carboplatin as a salvage therapy for platinum-pretreated patients with non-small cell lung cancer[J].Lung Cancer，2010，70(1)：71-6. [5] Zhang H,Feng WN,Deng YM,et al.Efficacy of pemetrexed plus cisplatin on chemotherapy-naive patients with advanced nonsquamous non- small cell lung cancer [J].Zhong Liu Fang Zhi Yan Jiu，2012,39(1)：88-90. [张华，冯卫能，邓燕明，等.培美曲塞联合顺铂一线治疗晚期非鳞状非小细胞肺癌的疗效观察[J].肿瘤防治研究，2012，39(1) ：88-90.] [6] Sun Y,Shi YK.Handbook of clinical tumor department of internal medicine[M].Beijing:People′s Medical Publishing House,2007:840-6.[孙燕，石远凯.临床肿瘤内科手册[M].北京：人民卫生出版社，2007：840-6.] [7] Yang H.Study of the peripheral blood T lymphocyte subsets using flow cytometry in 25 lung cancer patients[J ].Zhongguo Shi Yong Yi Yao,2009,4(26):36-7. [杨红.流式细胞术检测25例肺癌患者T淋巴细胞亚群表型分析[J].中国实用医药，2009，4(26)：36-7.] [8] Yan X,Zhao X,Jiao SC,et al. Clinical significance of T lymphocyte subset changes after first line chemotherapy in peripheral blood from patients with advanced stage adenocarcinoma cell lung cancer[J].Zhongguo Fei Ai Za Zhi,2012,15(3):164-71.[燕翔，赵晓，焦顺昌，等.晚期肺腺癌患者一线化疗后T淋巴细胞亚群变化及临床意义[J]. 中国肺癌杂志，2012，15(3):164-71.] [9] Xie ZJ,Xue ZZ,Yang LP.Progress in research of immune reconstitution and its significance after chemotherapy[ J].Zhongguo Quan Ke Yi Xue，2011,14(3):320-2．[谢治军，薛重重，杨丽萍.化疗后肿瘤免疫格局的改变及其意义的研究进展[J].中国全科医学，2011，14(3)：320-2.] [10] Chu YW,Wen JD,Xiong SD. Changed pattern of tumor immunity under lymphopenia setting and its significance in cancer biotherapy[J].Zhongguo Zhong Liu Sheng Wu Zhi Liao Za Zhi,2007,14(1):7-13．[储以微，温锦娣，熊思东.淋巴 细胞减少状态下的肿瘤免疫格局改变及其意义[J].中国肿瘤生物治疗杂志，2007，14(1)：7-13.] [11] Mazzoccoli G，Balzanelli M，Giuliani A，et al.Lymphocyte subpopulations anomalies in lung cancer patients and relationship to the stage of disease [J]. In Vivo，1999，13(3)：205-9. [12] Mo JY,Zhu QY,Zhuang YQ,et al. Effects of neoadjuvant chemotherapy on T-lymphocyte subgroup immunity in patients with advanced breast cancer[J].Shi Yong Ai Zheng Za Zhi，2007,22(5):454-6.[莫军扬，朱其一，庄亚强，等. 新辅助化疗对晚期乳腺癌患者T淋巴细胞亚群免疫功能的影响[J].实用癌症杂志，2007，22(5):454-6.] [13] Liu H，Zhang T，Ye J，et al.Tumor-infiltrating lymphocytes predict response to chemotherapy in patients with advance non-small cell lung cancer [J].Cancer Immunol Immunother，2012，61(10)：1849-56. [14] Luo J,Ling ZQ,Mao WM. Circulating lymphocyte subsets in patients with lung cancer and their prognostic value[J].Zhongguo Fei Ai Za Zhi，2011,14(8):669-73.[罗君，凌志强，毛伟敏.肺癌患者淋巴细胞亚群在外周血中的表达及其与 预后的关系[J].中国肺癌杂志，2011，14(8)：669-73.]
计量
- 文章访问数: 1935
- HTML全文浏览量: 24
- PDF下载量: 580
下载:
